Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.35 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GBA1 | P04062 | 2/20 | 0.34 |
| ▸ | UGCG | Q16739 | 2/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.34 |
| ▸ | RHEB | Q15382 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9238273 | 0.98 | PRMT5 (0.43) | PRMT5WDR77USP2SLC1A3SLC1A2 | |
| SCHEMBL7401026 | 0.98 | PRMT5 (0.43) | PRMT5WDR77USP2SLC1A3SLC1A2 | |
| SCHEMBL21810996 | 0.90 | USP2 (0.44) | PRMT5WDR77USP2LMNA | |
| SCHEMBL8737334 | 0.84 | USP2 (0.40) | PRMT5WDR77USP2LMNA | |
| SCHEMBL9652887 | 0.84 | USP2 (0.40) | PRMT5WDR77USP2LMNA | |
| SCHEMBL3893240 | 0.82 | USP2 (0.36) | PRMT5WDR77USP2 | |
| SCHEMBL24729200 | 0.81 | PRMT5 (0.44) | PRMT5WDR77LMNA | |
| SCHEMBL21402614 | 0.81 | USP2 (0.42) | PRMT5WDR77USP2LMNA | |
| SCHEMBL13459004 | 0.81 | USP2 (0.46) | PRMT5WDR77USP2 | |
| SCHEMBL13459028 | 0.79 | USP2 (0.49) | USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110225739-B | Wrinkle-improving agent | 宝丽化成工业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-10813859-B2 | Wrinkle ameliorating agent | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2020-10-27 | — | — | US | disclosed |
| EP-3545942-A1 | WRINKLE AMELIORATING AGENT | Pola Chemical Industries Inc. (JP) | 2019-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813859-B2 | Wrinkle ameliorating agent | COL2A1, COL1A1, COL14A1 | PRMT5 390/4885WDR77 1037/4885USP2 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.